Advertisement
Advertisement
U.S. markets close in 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Enveric Biosciences, Inc. (ENVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3100+0.0900 (+2.13%)
As of 03:12PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close4.2200
Open4.3000
Bid4.3100 x 2200
Ask4.4500 x 1200
Day's Range4.1301 - 4.4020
52 Week Range4.1301 - 112.5000
Volume23,457
Avg. Volume440,081
Market Cap8.957M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.6670
Earnings DateNov 21, 2022 - Nov 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 23, 2008
1y Target Est32.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ENVB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Enveric Biosciences, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Utilities Control the Path to Decarbonization, REIT Sector's relationship With Inflation and Interest Rates, Contract Research Organizations Are Poised for Healthy Growth, and Sony/Nintendo, VF Company, and Burberry
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Business Wire

    Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

    CAMBRIDGE, Mass., August 31, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Avani Kanubaddi, President & COO of Enveric, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

  • Business Wire

    Enveric Biosciences Appoints New Independent Directors

    CAMBRIDGE, Mass., July 27, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors.

  • Business Wire

    Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

    CAMBRIDGE, Mass., July 26, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), priced at a premium to market under Nasdaq rules. In addition, the Company

Advertisement
Advertisement